SABCS 2022 | HER2-low as a separate entity for defining HER2 BC and its prognostic and biological significance

Adam Brufsky, MD, PhD, University of Pittsburgh, Pittsburgh, PA, discusses the ongoing debate on HER2-low as a separate entity for defining HER2 breast cancer and its prognostic and biological significance. Although HER2-low is unlikely to be a separate entity, Dr Brufsky emphasizes that this does not diminish the utility of HER2-low as a biomarker of response to trastuzumab deruxtecan (T-DXd). This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.